Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.

Elisabetta PatornoAjinkya PawarDeborah J WexlerRobert J GlynnLily G BessetteJulie M PaikMehdi NajafzadehKimberly G BrodoviczAnouk Déruaz-LuyetSebastian Schneeweiss

Published in: Diabetes, obesity & metabolism (2021)

In clinical practice, the initiation of empagliflozin versus a DPP-4 inhibitor was associated with a lower risk of HHF, ACM and MI/stroke/ACM, a similar risk of MI/stroke, and a safety profile consistent with documented information.

Keyphrases

clinical practice
atrial fibrillation
end stage renal disease
ejection fraction
newly diagnosed
healthcare
chronic kidney disease
prognostic factors
peritoneal dialysis
pain management
patient reported outcomes
patient reported
blood brain barrier